The association between dysregulated microRNAs (miRNAs) and acute myeloid leukemia (AML) is well known. However, our understanding of the regulatory role of miRNAs in the cytogenetically normal AML (CN-AML) subtype pathway is still poor. The current study integrated miRNA and mRNA profiles to explore novel miRNA-mRNA interactions that affect the regulatory patterns of de novo CN-AML.
Methods:
We utilized a multiplexed nanoString nCounter platform to profile both miRNAs and mRNAs using similar sets of patient samples (n = 24). Correlations were assessed, and an miRNA-mRNA network was constructed. The underlying biological functions of the mRNAs were predicted by gene enrichment. Finally, the interacting pairs were assessed using TargetScan and microT-CDS. We identified 637 significant negative correlations (false discovery rate <0.05).
Results:
Network analysis revealed a cluster of 12 miRNAs representing the majority of mRNA targets. Within the cluster, five miRNAs (miR-495-3p, miR-185-5p, let-7i-5p, miR-409-3p, and miR-127-3p) were posited to play a pivotal role in the regulation of CN-AML, as they are associated with the negative regulation of myeloid leukocyte differentiation, negative regulation of myeloid cell differentiation, and positive regulation of hematopoiesis.
Conclusion:
Three novel interactions in CN-AML were predicted as let-7i-5p:HOXA9, miR-495-3p:PIK3R1, and miR-495-3p:CDK6 may be responsible for regulating myeloid cell differentiation in CN-AML.
Get full access to this article
View all access options for this article.
References
1.
ArberDA, OraziA, HasserjianR, et al. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127:2391-2405.
2.
BarhD, MalhotraR, RaviB, et al. (2010) Microrna let-7: an emerging next-generation cancer therapeutic. Curr Oncol, 17:70-80.
3.
CaligiuriMA, StroutMP, LawrenceD, et al. (1998) Rearrangement of ALL1 (MLL) in Acute Myeloid Leukemia with Normal Cytogenetics. Cancer Res, 58:55-59.
4.
Cancer Genome Atlas Research Network; LeyTJ, MillerC, DingL, et al. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368:2059-2074.
5.
CattaneoM, PelosiE, CastelliG, et al. (2015) A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes. J Cell Physiol, 230:1770-1780.
6.
ChenH, WangX, BaiJ, et al. (2017) Expression, regulation and function of miR-495 in healthy and tumor tissues. Oncol Lett, 13:2021-2026.
7.
Chhabra RJ Sr (2018) let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer. Sci Rep, 8:1-9.
8.
ChiyomaruT, YamamuraS, ZamanMS, et al. (2012) Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151. PLoS One, 7:e43812.
9.
ChuangM, ChiuY, ChouW, et al. (2015) A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. Leukemia, 29:1051-1059.
10.
CollinsCT, HessJL (2016) Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene, 35:1090-1098.
11.
de LeeuwDC, DenkersF, OlthofMC, et al. (2014) Attenuation of microRNA-126 Expression That Drives CD34 + 38− stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. J Cancer Res, 74:2094-2105.
12.
Díaz-BeyáM, BrunetS, NomdedéuJ, et al. (2014) MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia, 28:804-812.
13.
DingH-x, LvZ, YuanY, et al. (2018) MiRNA polymorphisms and cancer prognosis: a systematic review and meta-analysis. Front Oncol, 8:596.
14.
DufresneS, RébillardA, MutiP, et al. (2018) A review of physical activity and circulating miRNA expression: implications in cancer risk and progression. Cancer Epidemiol Biomarkers Prev, 27:11-24.
FuL, FuH, ZhouL, et al. (2016) High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep, 6:34546.
17.
FujimotoT, AndersonK, JacobsenSEW, et al. (2007) Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPα interaction. EMBO J, 26:2361-2370.
18.
GadewalN, KumarR, AherS, et al. (2020) miRNA-mRNA Profiling Reveals Prognostic Impact of SMC1A Expression in Acute Myeloid Leukemia. Oncol Res, 28:321-330.
19.
GoldbergAD, CollinsRH, StoneRM, et al. (2018) Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML. Blood 132(Suppl, 1):1436.
20.
GuJ, WangY, WuXJCpd (2013) MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des, 19:1292-1300.
21.
HanahanD, WeinbergRA (2000) The Hallmarks of Cancer. Cell, 100:57-70.
22.
HoangVT, Zepeda-MorenoA, HoADJBj (2012) Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. Biotechnol J, 7:779-788.
23.
HsuK-W, FangW-L, HuangK-H, et al. (2016) Notch1 pathway-mediated microRNA-151-5p promotes gastric cancer progression. Oncotarget, 7:38036.
24.
IacovinoM, HernandezC, XuZ, et al. (2009) A conserved role for hox paralog group 4 in regulation of hematopoietic progenitors. Stem Cells Dev, 18:783-792.
25.
IorioMV, CroceCM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med, 4:143-159.
26.
JiangX, HuangH, LiZ, et al. (2012) MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA, 109:19397-19402.
27.
JungD, KimB, FreishtatRJ, et al. (2015) miRTarVis: an interactive visual analysis tool for microRNA-mRNA expression profile data. BMC Proc 9(Suppl, 6):S2.
28.
KrellJ, FramptonAE, JacobJ, et al. (2012) The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Mol Diagn Ther, 16:167-172.
29.
KroonE, KroslJ, ThorsteinsdottirU, et al. (1998) Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J, 17:3714-3725.
30.
KubotaY, OhnishiH, KitanakaA, et al. (2004) Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia, 18:1438.
31.
LiY, JinX, WangZ, et al. (2019) Systematic review of computational methods for identifying miRNA-mediated RNA-RNA crosstalk. Brief Bioinform, 20:1193-1204.
32.
LinH, RotheK, ChenM, et al. (2020) The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. Blood, 136:596-609.
33.
LiuP, ChengH, RobertsTM, et al. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 8:627-644.
34.
MarcucciG, MrózekK, RadmacherMD, et al. (2011) The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood, 117:1121-1129.
35.
Mat YusoffY, Abu SemanZ, OthmanN, et al. (2019) Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. Asian Pac J Cancer Prev, 20:1749-1755.
36.
McNallyME, CollinsA, WojcikSE, et al. (2013) Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma. HPB (Oxford), 15:260-264.
37.
MerkerovaMD, KrejcikZ, BelickovaM, et al. (2015) Genome-wide mi RNA profiling in myelodysplastic syndrome with del (5q) treated with lenalidomide. Eur J Haematol, 95:35-43.
38.
MiH, MuruganujanA, EbertD, et al. (2018) PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. J Nucleic Acids Res, 47:D419-D426.
39.
MishraS, SrivastavaAK, SumanS, et al. (2015) Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett, 369:67-75.
40.
MukakaMM (2012) A guide to appropriate use of Correlation coefficient in medical research. Malawi Med J, 24:69-71.
41.
NiederwieserC, KohlschmidtJ, VoliniaS, et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia, 29:567-575.
42.
ParkS-M, ShellS, RadjabiAR, et al. (2007) Let-7 Prevents Early Cancer Progression by Suppressing Expression of the Embryonic Gene HMGA2. Cell Cycle, 6:2585-2590.
43.
PlackeT, FaberK, NonamiA, et al. (2014) Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 124:13-23.
44.
RiccioniR, LulliV, CastelliG, et al. (2015) miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias. Leukemia Res, 39:221-228.
45.
Riffo-CamposÁL, RiquelmeI, Brebi-MievilleP (2016) Tools for Sequence-Based miRNA Target Prediction: what to Choose?. Int J Mol Sci, 17:1987.
46.
ScheicherR, Hoelbl-KovacicA, BelluttiF, et al. (2015) CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood, 125:90-101.
47.
TanA, LuoR, RuanP (2019) miR-495 promotes apoptosis and inhibits proliferation in endometrial cells via targeting PIK3R1. Patho Res Pract, 215:594-599.
48.
The Gene Ontology Consortium (2016) Expansion of the Gene Ontology knowledgebase and resources. J Nucleic Acids Res, 45:D331-D338.
49.
ThorsteinsdottirU, MamoA, KroonE, et al. (2002) Overexpression of the myeloid leukemia-associate Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood, 99:121-129.
50.
TrinoS, LamorteD, CaivanoA, et al. (2018) MicroRNAs as new biomarkers for diagnosis and prognosis, and as potential therapeutic targets in acute myeloid leukemia. Int J Mol Sci, 19:460.
51.
UrasIZ, WalterGJ, ScheicherR, et al. (2016) Palbociclib treatment of FLT3-ITD AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood, 127:2890-2902.
52.
Veldman-JonesMH, BrantR, RooneyC, et al. (2015) Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res, 75:2587-2593.
53.
ViswanathanSR, DaleyGQ, GregoryRI (2008) Selective blockade of microRNA processing by Lin28. Science, 320:97-100.
54.
WallaceJA, KageleDA, EiringAM, et al. (2017) miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood, 129:3074-3086.
55.
WongKK, LawrieCH, GreenTMJBi (2019) Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia. Biomark Insights, 14:1177271919846454.
56.
XuQ, SimpsonS-E, SciallaTJ, et al. (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. J Blood, 102:972-980.
57.
YangHD, KimHS, KimSY, et al. (2019) HDAC6 suppresses Let-7i-5p to elicit TSP1/CD47-mediated anti-tumorigenesis and phagocytosis of hepatocellular carcinoma. Hepatology, 70:1262-1279.
58.
YangZ, ZhangY, WangLJPo (2013) A feedback inhibition between miRNA-127 and TGFβ/c-Jun cascade in HCC cell migration via MMP13. PLoS One, 8:e65256.
59.
YehT-C, HuangT-T, YehT-S, et al. (2016) miR-151-3p targets TWIST1 to repress migration of human breast cancer cells. PLoS One, 11:e0168171.
60.
YoonJ-H, KimJ, GorospeM (2015) Long noncoding RNA turnover. Biochimie, 117:15-21.
61.
ZhangH, ZhuM, ShanX, et al. (2019) A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis. Gene, 687:246-254.
62.
ZhangW, LiuY, ZhangJ, et al. (2020) Long Non-Coding RNA Taurine Upregulated Gene 1 Targets miR-185 to regulate cell proliferation and glycolysis in acute myeloid leukemia cells in vitro. Onco Targets Ther, 13:7887-7896.
63.
ZhangY, ChenA, YanX-M, et al. (2012) Disordered epigenetic regulation in MLL-related leukemia. Intl J Hematol, 96:428-437.
64.
ZhouJ, BiC, ChingYQ, et al. (2017a) Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia. J Hematol Oncol, 10:138.
65.
ZhouJ, ChanZ-L, BiC, et al. (2017b) LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML. J Mol Cancer Res, 15:294-303.
66.
ZhuR, LinW, ZhaoW, et al. (2019) A 4-microRNA signature for survival prognosis in pediatric and adolescent acute myeloid leukemia. J Cell Biochem, 120:3958-3968.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
